About this Journal Submit a Manuscript Table of Contents
Arthritis
Volume 2014 (2014), Article ID 432463, 13 pages
http://dx.doi.org/10.1155/2014/432463
Review Article

Glucosamine for Osteoarthritis: Biological Effects, Clinical Efficacy, and Safety on Glucose Metabolism

1Endocrine and Metabolic Diseases Research Center, Faculty of Medicine, University of Zulia, Maracaibo 4004, Venezuela
2Institute of Clinical Immunology, University of Los Andes, Mérida 5101, Venezuela

Received 29 September 2013; Accepted 20 December 2013; Published 11 February 2014

Academic Editor: Jiri Vencovsky

Copyright © 2014 Juan Salazar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Poley González, J. A. Ortega Blanco, M. Pedregal González, et al., “Prevalencia de enfermedades osteoarticulares y consumo de recursos. Calidad de vida y dependencia en pacientes con artrosis,” Semergen, vol. 37, no. 9, pp. 462–467, 2011.
  2. Guía Clínica, Tratamiento Médico en personas de 55 años y más con Artrosis de Cadera y/o rodilla, Leve o Moderada, Minsal, Santiago, Chile, 2007, http://web.minsal.cl/portal/url/item/a01c4b10a7c5219ae04001011f017145.pdf.
  3. M. Comas, M. Sala, R. Roman, et al., “Variaciones en la estimación de la prevalencia de artrosis de rodilla según los criterios diagnósticos utilizados en los estudios poblacionales,” Gaceta Sanitaria, vol. 24, no. 1, pp. 28–32, 2010.
  4. Centro Nacional de Enfermedades Reumáticas, Venezuela, 2010, http://www.cner.org.ve/pdf/reporte_2010.pdf.
  5. “Guía de práctica clínica para el diagnóstico y tratamiento de la osteoartrosis de rodilla,” Secretaria de Salud, Mexico City, México, 2008, http://www.cvsp.cucs.udg.mx/guias/TODAS/IMSS_079_08_OSTEOARTROSIS_RODILLA/IMSS_079_08_EyR.pdf.
  6. S. H. Hassanali and G. O. Oyoo, “Osteoarthritis: a look at pathophysiology and approach to new treatments: a review,” East African Orthopaedic Journal, vol. 5, pp. 51–57, 2011.
  7. S. Glasson, “Identification of targets through histologic evaluation of osteoarthritis in knockout mice,” Osteoarthritis Cartilage, vol. 13, supplement A, p. S3, 2005.
  8. “Annual nutrition industry overview,” Nutrition Business Journal, vol. 10, pp. 6–7, 2005.
  9. F. Guilak, “Biomechanical factors in osteoarthritis,” Best Practice and Research, vol. 25, no. 6, pp. 815–823, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Pulsatelli, O. Addimanda, V. Brusi, et al., “New findings in osteoarthritis pathogenesis: therapeutic implications,” Therapeutic Advances in Chronic Disease, vol. 4, no. 1, pp. 23–43, 2013.
  11. A. C. Bay-Jensen, S. Hoegh-Madsen, E. Dam et al., “Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?” Rheumatology International, vol. 30, no. 4, pp. 435–442, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. G. Ehrlich, H. J. Mankin, H. Jones, et al., “Collagenase and collagenase inhibitors in osteoarthritic and normal human cartilage,” Journal of Clinical Investigation, vol. 59, no. 2, pp. 226–233, 1977. View at Scopus
  13. L. C. Tetlow, D. J. Adlam, and D. E. Woolley, “Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes,” Arthritis & Rheumatology, vol. 44, pp. 585–594, 2001.
  14. J. P. Pelletier, J. Martel-Pelletier, and S. B. Abramson, “Osteoarthritis, an inflammatory disease. Potential implication for the selection of new therapeutic targets,” Arthritis & Rheumatology, vol. 44, pp. 1237–1247, 2001.
  15. J. P. Schroeppel, J. D. Crist, H. C. Anderson, and J. Wang, “Molecular regulation of articular chondrocyte function and its significance in osteoarthritis,” Histology and Histopathology, vol. 26, no. 3, pp. 377–394, 2011. View at Scopus
  16. R. M. Aspden, B. A. A. Scheven, and J. D. Hutchison, “Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism,” The Lancet, vol. 357, no. 9262, pp. 1118–1120, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. W. B. van den Berg, “Osteoarthritis year 2010 in review: pathomechanisms,” Osteoarthritis and Cartilage, vol. 19, no. 4, pp. 338–341, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. V. Goycochea, V. M. López, M. Colin-Marin, et al., “Guía clínica en osteoartrosis de rodilla y cadera,” Revista Médica del Instituto Mexicano del Seguro Social, vol. 41, suplement, pp. S99–S107, 2003.
  19. The Royal Australian College of General Practitioners, Guideline for the Non-Surgical Management of Hip and Knee Osteoarthritis, 2009, http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp117-hip-knee-osteoarthritis.pdf.
  20. W. Zhang, R. W. Moskowitz, G. Nuki et al., “OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines,” Osteoarthritis and Cartilage, vol. 16, no. 2, pp. 137–162, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Christensen, E. M. Bartels, A. Astrup, and H. Bliddal, “Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis,” Annals of the Rheumatic Diseases, vol. 66, no. 4, pp. 433–439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. T. P. Stitik, E. Altschuler, and P. M. Foye, “Pharmacotherapy of osteoarthritis,” American Journal of Physical Medicine and Rehabilitation, vol. 85, supplement, no. 11, pp. S15–S28, 2006. View at Scopus
  23. K. M. Jordan, N. K. Arden, M. Doherty et al., “EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT),” Annals of the Rheumatic Diseases, vol. 62, no. 12, pp. 1145–1155, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Mongil, I. Sánchez, F. Torre, et al., “Fármacos de acción lenta (Sysadoa) en el tratamiento de la osteoartrosis,” Revista de la Sociedad Española del Dolor, vol. 7, pp. 485–496, 2006.
  25. B. L. Kidd, R. M. Langford, T. Wodehouse, et al., “Current approaches in the treatment of arthritic pain,” Arthritis Research and Therapy, vol. 9, no. 3, article 214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. Ministry of Health Singapore (MOH), “Clinical practice guidelines Osteoarthritis of the knee,” 2007, http://www.moh.gov.sg/cpg.
  27. National Prescribing Service (NPS), “Analgesic choices in persistent pain. Prescribing Practice Review,” 2006, http://www.nps.org.au/publications/health-professional/prescribing-practice-review/2006/analgesic-choices-in-persistent-pain.
  28. E. M. Antman, J. S. Bennett, A. Daugherty, C. Furberg, H. Roberts, and K. A. Taubert, “Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association,” Circulation, vol. 115, no. 12, pp. 1634–1642, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Tanaka, C. Hamanishi, H. Kikuchi, and K. Fukuda, “Factors related to degradation of articular cartilage in osteoarthritis: a review,” Seminars in Arthritis and Rheumatism, vol. 27, no. 6, pp. 392–399, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. F. J. Blanco, R. Guitian, E. Vazquez-Martul, F. J. de Toro, and F. Galdo, “Osteoarthritis chondrocytes die by apoptosis,” Arthritis & Rheumatology, vol. 41, pp. 284–289, 1998.
  31. T. E. Towheed, L. Maxwell, T. P. Anastassiades et al., “Glucosamine therapy for treating osteoarthritis,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD002946, 2005. View at Scopus
  32. S. C. Vlad, M. P. LaValley, T. E. McAlindon, and D. T. Felson, “Glucosamine for pain in osteoarthritis: why do trial results differ?” Arthritis and Rheumatism, vol. 56, no. 7, pp. 2267–2277, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. E. A. Heath-Heckman and M. J. McFall-Ngai, “The occurrence of chitin in the hemocytes of invertebrates,” Zoology, vol. 114, no. 4, pp. 191–198, 2011.
  34. J. W. Anderson, R. J. Nicolosi, and J. F. Borzelleca, “Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy,” Food and Chemical Toxicology, vol. 43, no. 2, pp. 187–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Marshall, V. Bacote, and R. R. Traxinger, “Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system: role of hexosamine in the induction of insulin resistance,” The Journal of Biological Chemistry, vol. 266, no. 8, pp. 4706–4712, 1991. View at Scopus
  36. R. Kornfeld, “Studies on L-glutamine D-fructose 6-phosphate amidotransferase. I. Feedback inhibition by uridine diphosphate-N-acetylglucosamine,” The Journal of Biological Chemistry, vol. 242, no. 13, pp. 3135–3141, 1967. View at Scopus
  37. G. Wu, T. E. Haynes, W. Yan, and C. J. Meininger, “Presence of glutamine:fructose-6-phosphate amidotransferase for glucosamine-6-phosphate synthesis in endothelial cells: effects of hyperglycaemia and glutamine,” Diabetologia, vol. 44, no. 2, pp. 196–202, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Uldry, M. Ibberson, M. Hosokawa, and B. Thorens, “GLUT2 is a high affinity glucosamine transporter,” FEBS Letters, vol. 524, no. 1–3, pp. 199–203, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Fülöp, R. B. Marchase, and J. C. Chatham, “Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system,” Cardiovascular Research, vol. 73, no. 2, pp. 288–297, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. E. D. Schleicher and C. Weigert, “Role of the hexosamine biosynthetic pathway in diabetic nephropathy,” Kidney International, Supplement, vol. 58, supplement 77, pp. S13–S18, 2000. View at Scopus
  41. G. D. Holt and G. W. Hart, “The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharidie linkage, O-linked GlcNAc,” The Journal of Biological Chemistry, vol. 261, no. 17, pp. 8049–8057, 1986. View at Scopus
  42. R. J. Copeland, J. W. Bullen, and G. W. Hart, “Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity,” American Journal of Physiology—Endocrinology and Metabolism, vol. 295, no. 1, pp. E17–E28, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. W. B. Dias and G. W. Hart, “O-GlcNAc modification in diabetes and Alzheimer's disease,” Molecular BioSystems, vol. 3, no. 11, pp. 766–772, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Milewski, “Glucosamine-6-phosphate synthase: the multi-facets enzyme,” Biochimica et Biophysica Acta, vol. 1597, no. 2, pp. 173–192, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. G. L. McKnight, S. L. Mudri, S. L. Mathewes et al., “Molecular cloning, cDNA sequence, and bacterial expression of human glutamine: fructose-6-phosphate amidotransferase,” The Journal of Biological Chemistry, vol. 267, no. 35, pp. 25208–25212, 1992. View at Scopus
  46. P. P. Sayeski and J. E. Kudlow, “Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-α gene transcription,” The Journal of Biological Chemistry, vol. 271, no. 25, pp. 15237–15243, 1996. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Zhou, Q. K. Huynh, R. T. Hoffman et al., “Regulation of glutamine: fructose-6-phosphate amidotransferase by cAMP-dependent protein kinase,” Diabetes, vol. 47, no. 12, pp. 1836–1840, 1998. View at Scopus
  48. M. J. Pouwels, J. R. Jacobs, P. N. Span, J. A. Lutterman, P. Smits, and C. J. Tack, “Short-term glucosamine infusion does not affect insulin sensitivity in humans,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 2099–2103, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. I. Setnikar and L. C. Rovati, “Absorption, distribution, metabolism and excretion of glucosamine sulfate: a review,” Arzneimittel-Forschung/Drug Research, vol. 51, no. 9, pp. 699–725, 2001. View at Scopus
  50. B. A. Biggee, C. M. Blinn, M. Nuite, J. E. Silbert, and T. E. McAlindon, “Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 2, pp. 260–262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Aghazadeh-Habashi, S. Sattari, F. Pasutto, and F. Jamali, “Single dose pharmacokinetics and bioavailability of glucosamine in the rat,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 5, no. 2, pp. 181–184, 2002. View at Scopus
  52. T. Pham, D. V. der Heijde, M. Lassere et al., “Outcome variables for osteoarthritis clinical trials: the OMERACT-OARSI set of responder criteria,” Journal of Rheumatology, vol. 30, no. 7, pp. 1648–1654, 2003. View at Scopus
  53. N. Bellamy, W. W. Buchanan, C. H. Goldsmith, J. Campbell, and L. W. Stitt, “Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee,” Journal of Rheumatology, vol. 15, no. 12, pp. 1833–1840, 1988. View at Scopus
  54. M. Dougados, “Monitoring osteoarthritis progression and therapy,” Osteoarthritis and Cartilage, vol. 12, supplement A, pp. S55–S60, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. M. J. Divins, “Mercado de antiartrósicos,” Farmacia Profesional, vol. 24, no. 1, pp. 40–44, 2010.
  56. E. J. Uitterlinden, H. Jahr, J. L. M. Koevoet et al., “Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants,” Osteoarthritis and Cartilage, vol. 14, no. 3, pp. 250–257, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. L. C. Rovati, F. Girolami, and S. Persiani, “Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties,” Therapeutic Advances in Musculoskeletal Disease, vol. 4, no. 3, pp. 167–180, 2012.
  58. R. Calvo, “Sulfato de glucosamina y condroitín sulfato, fármacos para el tratamiento de la artrosis, acusados de no presentar eficacia clínica. ¿Culpables?” Gaceta Médica de Bilbao, vol. 109, no. 4, pp. 158–164, 2012.
  59. C. Black, C. Clar, R. Henderson et al., “The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation,” Health Technology Assessment, vol. 13, no. 52, pp. 1–123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. Sociedad Uruguaya de Reumatología (SUR), “Utilidad de los antiartrósicos de acción lenta en el tratamiento de la artrosis,” Carta Reumatológica, vol. 3, no. 1, pp. 1–40, 2012, http://www.reumauruguay.org/web/images/carta_reumatologica_2012.pdf.
  61. F. Abad Santos, D. Ochoa, and A. García García, “Actualización de la eficacia de condroitín sulfato y sulfato de glucosamina en el tratamiento de la artrosis,” Actualidad en farmacología y terapéutica, vol. 9, pp. 97–108, 2011.
  62. P. Tugwell, M. Boers, P. Brooks, L. Simon, V. Strand, and L. Idzerda, “OMERACT: an international initiative to improve outcome measurement in rheumatology,” Trials, vol. 8, article 38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Y. Reginster, R. Deroisy, L. C. Rovati et al., “Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial,” The Lancet, vol. 357, no. 9252, pp. 251–256, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. K. Pavelká, J. Gatterová, M. Olejarová, S. Machacek, G. Giacovelli, and L. C. Rovati, “Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study,” Archives of Internal Medicine, vol. 162, no. 18, pp. 2113–2123, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. O. Bruyere, K. Pavelka, L. C. Rovati et al., “Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials,” Osteoarthritis and Cartilage, vol. 16, no. 2, pp. 254–260, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Herrero-Beaumont, J. A. Román Ivorra, M. D. C. Trabado et al., “Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator,” Arthritis and Rheumatism, vol. 56, no. 2, pp. 555–567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. D. O. Clegg, D. J. Reda, C. L. Harris et al., “Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis,” The New England Journal of Medicine, vol. 354, no. 8, pp. 795–808, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. T. E. McAlindon, M. P. La Valley, J. P. Gulin, and D. T. Felson, “Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis,” Journal of the American Medical Association, vol. 283, no. 11, pp. 1469–1475, 2000. View at Scopus
  69. S. Wandel, P. Jüni, B. Tendal et al., “Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis,” British Medical Journal, vol. 341, Article ID c4675, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Giacovelli and L. C. Rovati, “Glucosamine and osteoarthritis. Conclusions not supported by methods and results,” British Medical Journal, vol. 341, Article ID c6338, 2010. View at Scopus
  71. J. Reginster, R. D. Altman, and M. C. Hochberg, “Glucosamine and osteoarthritis. Prescribed regimen is effective,” British Medical Journal, vol. 341, Article ID c6335, 2010. View at Scopus
  72. J. Reginster, A. Neuprez, M. Lecart, N. Sarlet, and O. Bruyere, “Role of glucosamine in the treatment for osteoarthritis,” Rheumatology International, vol. 32, no. 10, pp. 2959–2967, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Herontin, X. Chevalier, G. Herrero-Beaumont, et al., “Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities,” BMC Research Notes, vol. 6, article 115, 2013.
  74. Y. Henrotin, A. Mobasheri, and M. Marty, “Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?” Arthritis Research and Therapy, vol. 14, no. 1, article 201, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. K. Imagawa, M. C. de Andrés, K. Hashimoto et al., “The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-kB) inhibitor on primary human chondrocytes—implications for osteoarthritis,” Biochemical and Biophysical Research Communications, vol. 405, no. 3, pp. 362–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. A. R. Shikhman, K. Kuhn, N. Alaaeddine, and M. Lotz, “N-acetylglucosamine prevents IL-1β-mediated activation of human chondrocytes,” Journal of Immunology, vol. 166, no. 8, pp. 5155–5160, 2001. View at Scopus
  77. M. B. Goldring and M. Otero, “Inflammation in osteoarthritis,” Current Opinion in Rheumatology, vol. 23, no. 5, pp. 471–478, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Chan, J. P. Caron, and M. W. Orth, “Short-term gene expression changes in cartilage explants stimulated with interleukin 1β plus glucosamine and chondroitin sulfate,” Journal of Rheumatology, vol. 33, no. 7, pp. 1329–1340, 2006. View at Scopus
  79. V. Calamia, C. Ruiz-Romero, B. Rocha et al., “Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes,” Arthritis Research and Therapy, vol. 12, no. 4, article R138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. B. A. Biggee, C. M. Blinn, T. E. McAlindon, M. Nuite, and J. E. Silbert, “Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness,” Annals of the Rheumatic Diseases, vol. 65, no. 2, pp. 222–226, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. N. Ivanovska and P. Dimitrova, “Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine,” Arthritis Research and Therapy, vol. 13, no. 2, article R44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. E. C. Huskisson, “Glucosamine and chondroitin for osteoarthritis,” Journal of International Medical Research, vol. 36, no. 6, pp. 1161–1179, 2008. View at Scopus
  83. V. Matheu, M. T. Gracia Bara, R. Pelta, E. Vivas, and M. Rubio, “Immediate-hypersensitivity reaction to glucosamine sulfate,” Allergy, vol. 54, no. 6, p. 643, 1999. View at Scopus
  84. A. F. Tallia and D. A. Cardone, “Asthma exacerbation associated with glucosamine-chondroitin supplement,” Journal of the American Board of Family Practice, vol. 15, no. 6, pp. 481–484, 2002. View at Scopus
  85. T. Danao-Camara, “Potential side effects of treatment with glucosamine and chondroitin,” Arthritis and Rheumatism, vol. 43, no. 12, p. 2853, 2000. View at Scopus
  86. J. J. Manson and A. Rahman, “This house believes that we should advise our patients with osteoarthritis of the knee to take glucosamine,” Rheumatology, vol. 43, no. 1, pp. 100–101, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. M. G. Buse, “Hexosamines, insulin resistance, and the complications of diabetes: current status,” American Journal of Physiology—Endocrinology and Metabolism, vol. 290, no. 1, pp. E1–E8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. W. A. Lubas, D. W. Frank, M. Krause, and J. A. Hanover, “O-linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats,” The Journal of Biological Chemistry, vol. 272, no. 14, pp. 9316–9324, 1997. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Andreozzi, C. D'Alessandris, M. Federici et al., “Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic β-cells,” Endocrinology, vol. 145, no. 6, pp. 2845–2857, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. M. G. Buse, K. A. Robinson, B. A. Marshall, R. C. Hresko, and M. M. Mueckler, “Enhanced O-GlcNAc protein modification is associated with insulin resistance in GLUT1-overexpressing muscles,” American Journal of Physiology—Endocrinology and Metabolism, vol. 283, no. 2, pp. E241–E250, 2002. View at Scopus
  91. X. Yang, K. Su, M. D. Roos, Q. Chang, A. J. Paterson, and J. E. Kudlow, “O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 12, pp. 6611–6616, 2001. View at Publisher · View at Google Scholar · View at Scopus
  92. N. Lamarre-Vincent and L. C. Hsieh-Wilson, “Dynamic glycosylation of the transcription factor CREB: a potential role in gene regulation,” Journal of the American Chemical Society, vol. 125, no. 22, pp. 6612–6613, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. M. P. Housley, N. D. Udeshi, J. T. Rodgers et al., “A PGC-1α-O-GlcNAc transferase complex regulates FoxO transcription factor activity in response to glucose,” The Journal of Biological Chemistry, vol. 284, no. 8, pp. 5148–5157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. B. Laczy, B. G. Hill, K. Wang et al., “Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 296, no. 1, pp. H13–H28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. G. A. Ngoh, H. T. Facundo, A. Zafir, and S. P. Jones, “O-GlcNAc signaling in the cardiovascular system,” Circulation Research, vol. 107, no. 2, pp. 171–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. V. V. Lima, K. Spitler, H. Choi, R. C. Webb, and R. C. Tostes, “O-GlcNAcylation and oxidation of proteins: is signalling in the cardiovascular system becoming sweeter?” Clinical Science, vol. 123, no. 8, pp. 473–486, 2012.
  97. T. Monauni, M. G. Zenti, A. Cretti et al., “Effects of glucosamine infusion on insulin secretion and insulin action in humans,” Diabetes, vol. 49, no. 6, pp. 926–935, 2000. View at Scopus
  98. J. L. Stumpf and S. W. Lin, “Effect of glucosamine on glucose control,” Annals of Pharmacotherapy, vol. 40, no. 4, pp. 694–698, 2006.
  99. R. Muniyappa, R. J. Karne, G. Hall et al., “Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects,” Diabetes, vol. 55, no. 11, pp. 3142–3150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. D. A. Scroggie, A. Albright, and M. D. Harris, “The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial,” Archives of Internal Medicine, vol. 163, no. 13, pp. 1587–1590, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. S. G. Albert, R. F. Oiknine, S. Parseghian, A. D. Mooradian, M. J. Haas, and T. McPherson, “The effect of glucosamine on serum HDL cholesterol and apolipoprotein AI levels in people with diabetes,” Diabetes Care, vol. 30, no. 11, pp. 2800–2803, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. R. R. Simon, V. Marks, A. R. Leeds, and J. W. Anderson, “A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals,” Diabetes/Metabolism Research and Reviews, vol. 27, no. 1, pp. 14–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. N. R. Dostrovsky, T. E. Towheed, R. W. Hudson, and T. P. Anastassiades, “The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature,” Osteoarthritis and Cartilage, vol. 19, no. 4, pp. 375–380, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. T. Pham, A. Cornea, K. E. Blick, A. Jenkins, and R. H. Scofield, “Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance,” American Journal of the Medical Sciences, vol. 333, no. 6, pp. 333–339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. P. D. Marshall, S. Poddar, and E. M. Tweed, “Clinical inquiries: do glucosamine and chondroitin worsen blood sugar control in diabetes?” Journal of Family Practice, vol. 55, no. 12, pp. 1091–1093, 2006. View at Scopus
  106. R. P. dos Reis, G. Giacovelli, F. Girolami, R. André, A. Bonazzi, and L. C. Rovati, “Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence of long-term cardiovascular safety from clinical trials,” Open Rheumatology Journal, vol. 5, no. 1, pp. 69–77, 2011. View at Scopus
  107. G. A. Raciti, C. Iadicicco, L. Ulianich et al., “Glucosamine-induced endoplasmic reticulum stress affects GLUT4 expression via activating transcription factor 6 in rat and human skeletal muscle cells,” Diabetologia, vol. 53, no. 5, pp. 955–965, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. A. T. Sage, L. A. Walter, Y. Shi et al., “Hexosamine biosynthesis pathway flux promotes endoplasmic reticulum stress, lipid accumulation, and inflammatory gene expression in hepatic cells,” American Journal of Physiology—Endocrinology and Metabolism, vol. 298, no. 3, pp. E499–E511, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. D. R. Beriault, S. Sharma, Y. Shi, M. I. Khan, and G. H. Werstuck, “Glucosamine-supplementation promotes endoplasmic reticulum stress, hepatic steatosis and accelerated atherogenesis in apoE-/- mice,” Atherosclerosis, vol. 219, no. 1, pp. 134–140, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. D. R. Beriault and G. H. Werstuck, “The role of glucosamine-induced ER stress in diabetic atherogenesis,” Experimental Diabetes Research, vol. 2012, Article ID 187018, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. V. Ebrahim, M. Albeldawi, and D. J. Chiang, “Acute liver injury associated with glucosamine dietary supplement,” BMJ Case Reports, 2012. View at Publisher · View at Google Scholar